Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometry

Immunotherapies are revolutionizing cancer care, but many patients do not achieve durable responses and immune-related adverse events are difficult to predict. Quantifying the hundreds of proteins involved in cancer immunity has the potential to provide biomarkers to monitor and predict tumor respon...

Full description

Saved in:
Bibliographic Details
Published in:Scientific data 2024-06, Vol.11 (1), p.682-13, Article 682
Main Authors: Whiteaker, Jeffrey R., Zhao, Lei, Schoenherr, Regine M., Huang, Dongqing, Kennedy, Jacob J., Ivey, Richard G., Lin, Chenwei, Lorentzen, Travis D., Colantonio, Simona, Caceres, Tessa W., Roberts, Rhonda R., Knotts, Joseph G., Reading, Joshua J., Perry, Candice D., Garcia-Buntley, Sandra S., Bocik, William, Hewitt, Stephen M., Paulovich, Amanda G.
Format: Article
Language:English
Subjects:
631/67/1857
631/67/580
639/638/11/296
639/638/11/876
Antibodies, Monoclonal - immunology
Biomarkers
Cancer
Cancer immunotherapy
Clinical trials
Data Descriptor
Humanities and Social Sciences
Humans
Immune response
Immunomodulation
Immunotherapy
Mass Spectrometry
Mass spectroscopy
Monoclonal antibodies
multidisciplinary
Neoplasms - immunology
Proteins
Science
Science (multidisciplinary)
Scientific imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapies are revolutionizing cancer care, but many patients do not achieve durable responses and immune-related adverse events are difficult to predict. Quantifying the hundreds of proteins involved in cancer immunity has the potential to provide biomarkers to monitor and predict tumor response. We previously developed robust, multiplexed quantitative assays for immunomodulatory proteins using targeted mass spectrometry, providing measurements that can be performed reproducibly and harmonized across laboratories. Here, we expand upon those efforts in presenting data from a multiplexed immuno-oncology (IO)-3 assay panel targeting 43 peptides representing 39 immune- and inflammation-related proteins. A suite of novel monoclonal antibodies was generated as assay reagents, and the fully characterized antibodies are made available as a resource to the community. The publicly available dataset contains complete characterization of the assay performance, as well as the mass spectrometer parameters and reagent information necessary for implementation of the assay. Quantification of the proteins will provide benefit to correlative studies in clinical trials, identification of new biomarkers, and improve understanding of the immune response in cancer.
ISSN:2052-4463
2052-4463
DOI:10.1038/s41597-024-03467-x